India's customs department has formally aligned with the country's health ministry in an escalating regulatory dispute with the Adani Group over the distribution of nicotine pouches at airport duty-free outlets. The move signals a coordinated crackdown by multiple Indian government agencies against the billionaire Gautam Adani's sprawling infrastructure conglomerate, which operates eight airports across the nation and has positioned duty-free retail as a cornerstone of its commercial expansion strategy. The conflict centres on whether goods sold in international departure zones at airports enjoy immunity from domestic health laws, a question that will reshape how India's regulatory authorities approach the emerging global nicotine category within its borders.
The customs department filed a formal submission to judges at Mumbai's High Court on June 22, explicitly rejecting Adani's argument that duty-free shops operate in a regulatory grey zone. In their court filing, customs officials asserted that tax advantages granted to duty-free retailers do not confer broader exemptions from health and safety regulations applicable throughout Indian territory. This position directly contradicts Adani's legal strategy, which has centred on the argument that the international departure area of airports sits outside the jurisdiction of domestic regulatory frameworks. The customs submission represents a significant escalation in the dispute, transforming what began as a health ministry enforcement action into a multi-agency regulatory challenge that touches on fundamental questions about regulatory authority and corporate compliance.
The underlying facts of the case emerged in March when health officials conducted an inspection of duty-free operations at the Adani Group's Mumbai International Airport. Inspectors discovered that nicotine pouches were being sold to passengers in the airport's international departure zone, a finding that violated India's regulatory stance toward this emerging product category. Rather than accepting the compliance notice, Adani proceeded to challenge the health ministry's determination in Mumbai's High Court, arguing that the regulatory action lacked proper procedural foundation. In a subsequent filing dated July 13, obtained by Reuters, the Adani Group contended that customs authorities had ordered them to cease sales without issuing the procedurally required warning notice, thereby compromising the legitimacy of the enforcement action itself.
Adani's legal position rests on two interconnected arguments that attempt to create regulatory separation between airport operations and domestic law. First, the company has argued that goods sold in duty-free shops are positioned outside India's customs frontiers for taxation purposes and therefore outside the reach of domestic health regulations. Second, Adani has asserted that nicotine pouches sold by duty-free retailers are sealed and not intended for consumption within India, as purchasers are supposed to use these products only after departing the country and entering international airspace or foreign territory. This interpretation of duty-free commerce, if accepted by courts, would create a significant loophole in India's regulatory framework, allowing the sale of products otherwise prohibited domestically.
However, the customs department's June 22 filing dismantles this legal architecture by adopting a practical interpretation of consumer behaviour and regulatory obligation. Customs authorities pointed out that passengers who purchase duty-free goods gain physical possession and control of those items upon purchase, regardless of formal restrictions on use. Once passengers hold sealed bags containing nicotine pouches, they can freely choose to consume the products during their flight or after arriving in destination countries, making the theoretical distinction between sealed goods and actual consumption largely meaningless in practice. This reasoning transforms the debate from one about legal fictions to one about regulatory reality, suggesting that India cannot effectively enforce health restrictions on products it officially prohibits if those products are openly sold at airports operated by private companies.
The regulatory dispute carries significant implications for India's evolving relationship with nicotine products and emerging consumer categories. Nicotine pouches represent one of the world's fastest-growing nicotine delivery systems and have achieved substantial market penetration in numerous countries, particularly in North America and Northern Europe. Despite this global expansion, India has not approved nicotine pouches for domestic sale, reflecting the country's cautious approach to novel nicotine products and its commitment to existing tobacco control frameworks. Philip Morris International, the leading global manufacturer through its Zyn brand, has reported that sales nearly doubled year-on-year in the United States market during 2024, underscoring the commercial significance of this product category for international tobacco companies.
Adani's importation activities reveal the commercial stakes driving this regulatory confrontation. Since August, the company has imported Zyn and White Fox brand nicotine pouches from Swedish Smokeless Solutions, with documented import values exceeding $35,000. These imports suggest that Adani views duty-free distribution as a viable entry point for establishing a foothold in India's nicotine market, even as the product remains formally unapproved. The Adani Group's broader airport expansion strategy, which targets $11 billion in investment across its growing portfolio of airport concessions, increasingly depends on generating substantial non-aeronautical revenue from retail operations. Duty-free commerce, with its tax advantages and captive customer base of international travellers, represents a particularly attractive revenue stream within this expansion model.
The timing and structure of India's regulatory response reflect growing government vigilance toward corporate attempts to circumvent health regulations through procedural or jurisdictional arguments. The health ministry's March inspection and subsequent enforcement action initiated the dispute, but the customs department's formal court filing elevates the matter to the level of sustained inter-agency coordination. This approach suggests that Indian regulatory authorities view the Adani case not merely as an isolated compliance issue but as a test of whether multinational companies and large domestic enterprises can exploit regulatory ambiguities at airports to distribute products otherwise prohibited in domestic markets. The government's willingness to deploy multiple agencies and pursue the matter through court filings indicates determination to establish clear precedent.
The legal proceedings scheduled for July 28 at Mumbai's High Court will likely determine whether India's regulatory authority extends fully into airport duty-free zones or whether these spaces remain partially autonomous from domestic health frameworks. The court's decision will establish crucial precedent for how regulatory authority flows through airport infrastructure, a question with implications extending far beyond nicotine pouches to encompass any product category where imported goods might be sold to departing passengers. If courts rule that duty-free retailers remain subject to all domestic health regulations regardless of tax status, India will have closed a significant regulatory loophole and strengthened its capacity to enforce health policy across its entire territory. Conversely, a ruling favouring Adani's position would legitimise duty-free zones as regulatory sanctuaries, potentially inviting other companies to exploit similar ambiguities.
For Malaysia and other Southeast Asian nations monitoring India's regulatory approach, the Adani case illuminates ongoing tensions between corporate expansion strategies and governmental capacity to enforce health regulations across complex commercial infrastructure. As multinational companies increasingly seek to establish regional distribution networks for emerging product categories, regulatory authorities throughout Southeast Asia face similar questions about whether tax and trade benefits should confer broader regulatory exemptions. The Adani dispute demonstrates that courts and regulatory agencies are beginning to scrutinise such arguments more closely, reflecting growing recognition that regulatory frameworks must adapt to contemporary commercial structures and international supply chains.
